Apyx Medical reports preliminary Q4 revenue $19M-$19.2M, consensus $17.47M

“We are excited by AYON’s commercial launch, which delivered immediate momentum and contributed to a strong fourth quarter, including an increase of approximately 51% in revenue for our Surgical Aesthetics segment in the U.S.,” said Charlie Goodwin, President and CEO of Apyx Medical (APYX) Corporation. “With Renuvion and AYON now in the market, we are well-positioned to capitalize on the expected increase in aesthetic surgical procedures in the U.S. This positive industry momentum is being fueled, in part, by the adoption of GLP-1 therapies resulting in significant patient weight loss and loose and lax skin.”